前沿速览037期| CAR-T治B淋 前沿览新知
01
已获批的CD19 CAR-T细胞治疗大B细胞淋巴瘤的结局
Outcome correlates of approved CD19-targeted CAR T cells for large B cell lymphoma
第一作者：Bock TJ
Nat Rev Clin Oncol (IF=81.1). 2025 Feb 18.
全文网址：https://www.nature.com/articles/s41571-025-00992-5
02
滤泡性淋巴瘤管理：未来的策略
The Future of Follicular Lymphoma Management: Strategies on the Horizon
第一作者：Mulvey E
Blood (IF=21.1). 2025 Feb 28:blood.2024026017.
全文网址：https://ashpublications.org/blood/article-abstract/doi/10.1182/blood.2024026017/535794/The-Future-of-Follicular-Lymphoma-Management?redirectedFrom=fulltext
03
靶向PRC2可增强CD19 CAR-T细胞对血液系统恶性肿瘤的细胞毒性能力
Targeting PRC2 Enhances the Cytotoxic Capacity of Anti-CD19 CAR-T Cells Against Hematological Malignancies
第一作者：Carvalho MLR
Cancer Res (IF=12.5). 2025 Feb 19.
全文网址：https://aacrjournals.org/cancerres/article-abstract/doi/10.1158/0008-5472.CAN-24-1643/751986/Targeting-PRC2-Enhances-the-Cytotoxic-Capacity-of?redirectedFrom=fulltext
04
CD19 CAR-T细胞治疗复发/难治性原发纵隔大B细胞淋巴瘤患者的临床结局：一项来自法国DESCAR-T登记的CARTHYM研究
Outcomes of patients with relapsed or refractory primary mediastinal B-cell lymphoma treated with anti-CD19 CAR-T cells: CARTHYM, a study from the French national DESCAR-T registry
第一作者：Galtier J
Hemasphere (IF=11.9). 2025 Feb 18;9(2):e70091.
全文网址：https://pmc.ncbi.nlm.nih.gov/articles/PMC11833168/
05
CAR-T细胞治疗侵袭性B细胞非霍奇金淋巴瘤患者的晚期不良事件
Late Adverse Events After Chimeric Antigen Receptor T-Cell Therapy for Patients With Aggressive B-Cell Non-Hodgkin Lymphoma
第一作者：Camacho-Arteaga L
JAMA Netw Open (IF=10.5). 2025 Feb 3;8(2):e2461683.
全文网址：https://pmc.ncbi.nlm.nih.gov/articles/PMC11862965/
06
CAR-T细胞疗法联合泽布替尼治疗复发/难治性弥漫大B细胞淋巴瘤的疗效与安全性
Efficacy and safety of chimeric antigen receptor T cell therapy combined with zanubrutinib in the treatment of relapsed/refractory diffuse large B-cell lymphoma
第一作者：Wang L
Chin Med J (Engl) (IF=7.5). 2025 Feb 21.
全文网址：https://journals.lww.com/cmj/fulltext/9900/efficacy_and_safety_of_chimeric_antigen_receptor_t.1437.aspx
07
侵袭性大B细胞淋巴瘤患者在CAR-T细胞治疗前接受桥接放疗的临床结局
Outcomes with bridging radiation therapy prior to chimeric antigen receptor T-cell therapy in patients with aggressive large B-cell lymphomas
第一作者：Manzar GS
Front Immunol (IF=5.7). 2025 Jan 31;16:1517348.
全文网址：https://pmc.ncbi.nlm.nih.gov/articles/PMC11825444/
08
套细胞淋巴瘤：近5年的临床研究进展
Mantle Cell Lymphoma: what clinical progress in the last 5 years?
第一作者：Soueidy C
Expert Opin Investig Drugs (IF=4.9). 2025 Feb 24.
全文网址：https://www.tandfonline.com/doi/10.1080/13543784.2025.2472410?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed
09
在B细胞淋巴瘤临床前模型中, Capivasertib可增强CAR-T细胞的活性
Capivasertib enhances chimeric antigen receptor T cell activity in preclinical models of B cell lymphoma
第一作者：Hsieh HJ
Mol Ther Methods Clin Dev (IF=4.6). 2025 Jan 24;33(1):101421.
全文网址：https://pmc.ncbi.nlm.nih.gov/articles/PMC11850743/
10
肺功能检测在预测CAR-T细胞治疗后并发症中的作用
Role of Pulmonary Function Tests to Predict Complications After Chimeric Antigen Receptor T-Cell Therapy
第一作者：Walder J
Clin Lymphoma Myeloma Leuk (IF=2.7). 2025 Jan 28:S2152-2650(25)00037-0.
全文网址：https://www.clinical-lymphoma-myeloma-leukemia.com/article/S2152-2650(25)00037-0/abstract
免责声明：本资料为专业医学资料，旨在促进医药信息的沟通和交流，仅供医疗卫生专业人士参考；任何处方请参考产品最新详细处方资料。本文件可能包含涉及医学情况、健康及治疗方法的信息。相关信息不得用作诊断或治疗，不能替代专业医学意见。
审批编号：NP-NHL-2025.3-3 valid until 2027.3
供稿与审核：临床开发与医学部